Last reviewed · How we verify
Cannabis Sativa Oil
Cannabis Sativa Oil is a Phytocannabinoid preparation Small molecule drug developed by Fondation pour l'accueil et l'hébérement des personnes âgées. It is currently FDA-approved for Chronic pain, Neuropathic pain, Chemotherapy-induced nausea and vomiting.
Cannabis Sativa Oil contains phytocannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems.
Cannabis Sativa Oil contains phytocannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems. Used for Chronic pain, Neuropathic pain, Chemotherapy-induced nausea and vomiting.
At a glance
| Generic name | Cannabis Sativa Oil |
|---|---|
| Sponsor | Fondation pour l'accueil et l'hébérement des personnes âgées |
| Drug class | Phytocannabinoid preparation |
| Target | CB1 receptor, CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management, Neurology, Immunology |
| Phase | FDA-approved |
Mechanism of action
The oil's active cannabinoids bind to CB1 receptors in the brain and CB2 receptors in immune cells and peripheral tissues, modulating neurotransmitter release and immune function. This produces analgesic, anti-inflammatory, anxiolytic, and antiemetic effects. The specific therapeutic profile depends on the THC:CBD ratio and individual cannabinoid composition.
Approved indications
- Chronic pain
- Neuropathic pain
- Chemotherapy-induced nausea and vomiting
- Multiple sclerosis-related spasticity
Common side effects
- Dizziness
- Dry mouth
- Fatigue
- Impaired cognition
- Anxiety or paranoia
Key clinical trials
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Cannabidiol for Reduction of Brain Neuroinflammation (PHASE2)
- Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Cannabis (THC vs. CBD) in Multiple Sclerosis (PHASE2)
- Pilot Study of MC in Paediatric Palliative Care (PHASE1, PHASE2)
- Reducing Pain and Opioid Use With CBD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabis Sativa Oil CI brief — competitive landscape report
- Cannabis Sativa Oil updates RSS · CI watch RSS
- Fondation pour l'accueil et l'hébérement des personnes âgées portfolio CI
Frequently asked questions about Cannabis Sativa Oil
What is Cannabis Sativa Oil?
How does Cannabis Sativa Oil work?
What is Cannabis Sativa Oil used for?
Who makes Cannabis Sativa Oil?
What drug class is Cannabis Sativa Oil in?
What development phase is Cannabis Sativa Oil in?
What are the side effects of Cannabis Sativa Oil?
What does Cannabis Sativa Oil target?
Related
- Drug class: All Phytocannabinoid preparation drugs
- Target: All drugs targeting CB1 receptor, CB2 receptor
- Manufacturer: Fondation pour l'accueil et l'hébérement des personnes âgées — full pipeline
- Therapeutic area: All drugs in Pain management, Neurology, Immunology
- Indication: Drugs for Chronic pain
- Indication: Drugs for Neuropathic pain
- Indication: Drugs for Chemotherapy-induced nausea and vomiting
- Compare: Cannabis Sativa Oil vs similar drugs
- Pricing: Cannabis Sativa Oil cost, discount & access